<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718260</url>
  </required_header>
  <id_info>
    <org_study_id>4826</org_study_id>
    <nct_id>NCT03718260</nct_id>
  </id_info>
  <brief_title>PSMA-PET Registry for Recurrent Prostate Cancer</brief_title>
  <acronym>PREP</acronym>
  <official_title>PSMA-PET Registry for Recurrent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Care Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Probe Development and Commercialization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to institute a province-wide registry leveraging the availability of a new&#xD;
      Positron Emission Tomography tracer, [18F]-DCFPyL and PET expertise across Ontario centers to&#xD;
      improve our ability to characterize patterns of recurrence and personalize therapies in men&#xD;
      with recurrent prostate cancer after primary treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry study will provide Ontario centres access to a new Positron Emission Tomography&#xD;
      (PET) tracer, [18F]-DCFPyL, to improve our ability to identify areas of prostate cancer&#xD;
      recurrence in men who have undergone surgical removal of their prostate gland (radical&#xD;
      prostatectomy) or radiation of their prostate (external beam radiation, brachytherapy or a&#xD;
      combination of both) and there is a suspicion of recurrence of the cancer. Men with suspected&#xD;
      persistent or recurrent disease can be identified on the basis of a rising Prostate Specific&#xD;
      Antigen (PSA) blood test, or the presence of node positive disease at the time of their&#xD;
      surgery, or a PSA blood test continues to be detectable within 3 months after their surgery.&#xD;
      It is the aim of this study to determine if [18F]-DCFPyL PET/CT can potentially identify&#xD;
      areas of prostate cancer recurrence not seen with usual imaging (bone scan/CT scans) and&#xD;
      impact the management of the disease. A report of the results of the [18F]-DCFPyL PET/CT will&#xD;
      be provided to the participating physicians to determine a treatment plan. As part of the&#xD;
      patient eligibility for [18F]-DCFPyL PET/CT participating physicians will complete a&#xD;
      questionnaire after the [18F]-DCFPyL PET/CT information is provided to report how the results&#xD;
      impact patient management. Actual interventions following completion of the [18F]-DCFPyL&#xD;
      PET/CT will be tracked by linkage to provincial registries. Six centres across Ontario will&#xD;
      participate in the registry study which is expected to take 4 years to complete with an&#xD;
      additional one year of follow-up to capture patient outcomes.&#xD;
&#xD;
      PREP Phase 2 was initiated to investigate the hypothesis that conventional imaging is not&#xD;
      adding to the information provided by PSMA PET/CT alone. PREP Phase 2 will retain the same&#xD;
      study design as Phase I but will remove bone scan and computed tomography as criteria for&#xD;
      entry into the study except for those patients with higher PSA (&gt;10 ng/ml).&#xD;
&#xD;
      Identical cohort sizes will be accrued in Phase 2 to permit comparison of detection rates&#xD;
      with similar confidence intervals with and without conventional imaging. Transition to PREP&#xD;
      Phase 2 occurred when overall accrual to PREP exceeded 80% of target.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of disease detection on PSMA PET</measure>
    <time_frame>5 years</time_frame>
    <description>Phase 1: The number of men with detectable lesions on PSMA PET who have suspected recurrent or persistent disease post radical prostatectomy with or without adjuvant or salvage pelvic radiotherapy or hormone therapy as well as men treated with primary radiotherapy will be measured&#xD;
Phase 2: The number of men with detectable lesions on PSMA PET who have suspected recurrent or persistent disease post radical prostatectomy with or without adjuvant or salvage pelvic radiotherapy or hormone therapy as well as men treated with primary radiotherapy will be measured when PSMA PET/CT is used without routine pre-screening with conventional imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine correlations between PSA levels at time of imaging and presence of disease detected on PSMA PET.</measure>
    <time_frame>5 years</time_frame>
    <description>The likelihood of disease detected on PSMA PET will be correlated with absolute PSA level at the time of PSMA PET as supplied on the eligibility form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of men with oligometastatic recurrence (four or fewer sites including the prostate bed if positive) confirmed on PSMA PET/CT</measure>
    <time_frame>5 years</time_frame>
    <description>Number of men with four or fewer sites of disease detected on PSMA PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of men who have their management plan changed because of PSMA PET results</measure>
    <time_frame>5 years</time_frame>
    <description>The number of men who have a change in management as indicated by responses from referring physicians on an impact questionnaire completed after PSMA PET scans are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the actual management delivered within 6 months of PSMA PET</measure>
    <time_frame>5 years</time_frame>
    <description>Actual management within 6 months will be determined through linkage to existing health information registries and will include:&#xD;
Delivery of radiotherapy (anatomic site, dose and fractionation) - Cancer Care Ontario&#xD;
Biopsy of suspected recurrences (anatomic site, histology) - Provincial pathology database&#xD;
Use of salvage lymph node dissections - CIHI&#xD;
Use of salvage hormonal therapy/androgen deprivation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare PSA response at 6 months against PSA at the time of PSMA PET</measure>
    <time_frame>5 years</time_frame>
    <description>PSA response will be examined by comparing 6 month PSA against PSA at the time of PSMA PET through the Ontario Laboratory Information Services and correlated with actual management as determined in Outcome 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the detection rates of PSMA PET/CT when conventional imaging is used as part of the eligibility criteria (PREP) versus when conventional imaging is omitted (PREP Phase 2)</measure>
    <time_frame>5 years</time_frame>
    <description>Number of men with detectable lesions as determined in the primary objective for PREP will be compared to the number of men with detectable lesions as determined in primary objective for PREP Phase 2.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">3070</enrollment>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men who are node positive or who have persistently detectable PSA after initial radical prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men with biochemical failure after initial prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men with biochemical failure after initial radical prostatectomy and salvage radiotherapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men with biochemical failure after initial radical prostatectomy with or without adjuvant/ salvage radiotherapy who are currently on salvage hormone therapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men who have prior PSMA directed treatment for oligometastatic disease, such as lesion directed therapy (e.g. stereotactic radiosurgery) or systemic therapy (e.g. hormone therapy or chemotherapy) with subsequent biochemical failure will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men with biochemical failure after primary radiation therapy (external beam, brachytherapy or combinations together with or without hormone therapy) will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]-DCFPyL as a problem-solving tool in patients with prostate cancer when confirmation of the site of disease and/or disease extent may impact clinical management. Patients in this cohort require approval from an independent adjudication by Cancer Care Ontario.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[18F]-DCFPyL PET/ CT scan (PSMA PET)</intervention_name>
    <description>Participants will undergo re-staging with [18F]-DCFPyL PET/CT Scan (PSMA PET).</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 2&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained&#xD;
&#xD;
          2. Male, Age â‰¥ 18 years&#xD;
&#xD;
          3. Prior primary treatment for prostate cancer with curative intent such as radical&#xD;
             prostatectomy or radiotherapy for localized prostate cancer. Unless PET/CT requested&#xD;
             as part of Cohort 7.&#xD;
&#xD;
          4. Suspected persistent or recurrent disease defined as one of the following (unless&#xD;
             PET/CT requested as part of Cohort 7):&#xD;
&#xD;
               1. High risk disease at the time of radical prostatectomy characterized by&#xD;
                  pathologically involved node(s) or persistently detectable PSA (&gt;0.1ng/ml) within&#xD;
                  3 months post-surgery&#xD;
&#xD;
               2. Primary treatment for prostate cancer and biochemical failure (BF) with current&#xD;
                  management according to the following:&#xD;
&#xD;
             i. Following primary radical prostatectomy, BF is defined as rising PSA on at least 2&#xD;
             occasions measured at least 1 month apart and with the most recent PSA measured at&#xD;
             &gt;0.1 ng/ml&#xD;
&#xD;
             ii. Following primary radiotherapy for localized disease, BF is defined according to&#xD;
             the Phoenix Definition, which is rising PSA on at least 2 occasions measured at least&#xD;
             1 month apart and with the most recent PSA measured greater than the nadir PSA + 2.0&#xD;
             ng/ml&#xD;
&#xD;
          5. Patient scenario falls into one of the 7 pre-defined cohorts. When patient scenario&#xD;
             falls outside cohorts 1-6 participation in the Registry must be approved through the&#xD;
             established CCO adjudication process for Cohort 7.&#xD;
&#xD;
          6. Karnofsky performance status 70 or better (ECOG 0, 1).&#xD;
&#xD;
          7. If PSA &gt;10 mg/mL, conventional imaging consisting of bone scan and abdo-pelvic CT scan&#xD;
             within 3 months of registration that is either equivocal, negative (no lesions) or&#xD;
             positive for oligometastatic disease (4 or fewer unequivocal lesions identified).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small&#xD;
             cell components.&#xD;
&#xD;
          2. Prior PSMA PET scan within 6 months of enrollment.&#xD;
&#xD;
          3. Patient cannot lie still for at least 60 minutes or comply with imaging.&#xD;
&#xD;
          4. Patients falling outside of Cohorts 1-6 where independent adjudication by CCO does not&#xD;
             support participation in the Registry.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants must be male (prostate cancer)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Bauman, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ur Metser, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Hildebrand, PhD, Project Coordinator</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>53535</phone_ext>
    <email>catherine.hildebrand@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator- Camilla Tajzler</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35876</phone_ext>
      <email>tajzlec@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Anil Kapoor, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bobby Shayegan, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Associate- Stephanie Horst</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>56601</phone_ext>
      <email>stephanie.horst@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Joseph Chin, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glenn Bauman, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Assistant- David Yachnin</last_name>
      <phone>613-798-5555</phone>
      <phone_ext>74639</phone_ext>
      <email>dyachnin@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Luke Lavallee, MDCM, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugene Leung, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Morash, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator- Lori Moon, RN</last_name>
      <phone>807-684-7226</phone>
      <email>moonl@tbh.net</email>
    </contact>
    <investigator>
      <last_name>Marlon Hagerty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walid Shahrour, MD, RCPSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Boekhoud, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Coordinator- Marlene Kebabdjian</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>2890</phone_ext>
      <email>Marlene.Kebabdjian@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Laurence Klotz, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Wolfson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator- Linda Chan</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>5734</phone_ext>
      <email>Linda.Chan@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Antonio Finelli, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ur Metser, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Biochemical Failure</keyword>
  <keyword>Node positive</keyword>
  <keyword>PSMA-PET</keyword>
  <keyword>[18F]DCFPyL PET/CT imaging</keyword>
  <keyword>Radical Prostatectomy</keyword>
  <keyword>Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

